Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

September 30, 2025

Conditions
Chronic Kidney Diseases
Interventions
BIOLOGICAL

KDSTEM Inj.

"1. Low dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 1.0x10\^8 cells/10mL/2 syringes)~2. High dose: The following study drugs are pre-mixed with 70mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 3.0x10\^8 cells/30mL/6 syringes)"

Trial Locations (1)

Unknown

RECRUITING

Chungnam National University Hospital, Daejeon

All Listed Sponsors
lead

EHL Bio Co., Ltd.

INDUSTRY